from estimates for healthy volunteers possibly because of the physiologic changes as a result of surgery. Our findings suggest that meropenem (1,000 mg) administered intravenously every 8 h provides adequate concentrations for most intra-abdominal infections.
Meropenem (SM-7338) is a new carbapenem, similar to imipenem, with a spectrum of coverage including most enteric gram-negative bacilli, some gram-positive bacteria, and anaerobic bacteria (8, 11, 14) . One use for meropenem is the treatment of intra-abdominal infections, such as perforated or gangrenous appendicitis (18) . Very few trials have provided sufficient descriptions of pharmacokinetic parameters in patients. As quantitation of the plasma method was 0.500 p,g/ml, and the response from calibration standards was linear from 0.500 to 100 ,ug/ml. Some samples were reassayed after dilution with blank plasma because of initial values which exceeded the validated linear range of the method. Within-day variation at a concentration of 0.500 p,g/ml was 6.6%. At the high concentration of 100 ,ug/ml, the within-day variation was 5.7%. Between-day variation was 5.6 and 2.5% for 0.500 and 100 p,g/ml, respectively. The limit of quantitation of the urine method was 1.00 p,g/ml, and the response from calibration standards was linear from 1.00 to 500 ,ug/ml. After the initial urine assays for this study, samples were routinely diluted with blank urine prior to assay to minimize repeats.
Data were analyzed from noncompartmental modelling using the LAGRAN computer program (1) by using LAGRAN. Each patient's creatinine clearance (CLCR) was calculated by using the Cockroft-Gault equation (6) . Renal clearance (CLR) was calculated from the 4-h urine collection and the AUCA 4by using standard equations (17) .
The hybrid constants a and were calculated using standard equations (19) . The maximum serum drug concentration (Cm.x) was determined by visual inspection of the datum points.
Multicompartmental analysis was also performed by using the Adapt-ID3 computer program (7) . Weighted linear leastsquares regression with inverse variance of assay weighing was used to fit one-and two-compartment models. To select the best model describing meropenem disposition in our patients, we used the minimum Akaike information criterion estimate (21) and inspection of residual plots.
Of the 314 patients enrolled in the efficacy trial, 12 patients (one woman and 11 men) in the meropenem arm consented to this pharmacokinetic study. The healthy individuals who had peritonitis. The mean number of meropenem doses administered, prior to serum and urine sampling, was 5.9 + 1.8, ranging from 2 to 8 doses. Five of the twelve study patients experienced diarrhea during meropenem therapy. Three patients had increases in aspartate aminotransferase and alanine aminotransferase, and two patients had increases in alkaline phosphatase. However, in none of these patients was meropenem therapy discontinued because of an adverse drug reaction. The treatment of two patients in the meropenem clinical trial failed. Yet the estimated pharmacokinetic parameters in these 2 patients did not significantly differ from those in the other 10 study patients.
The minimum Akaike information criterion estimate indicated the two-compartment model as the best description of meropenem disposition in our study patients. Our selection of best fit was supported by visual inspection of the plots of standardized residuals versus time. We report two-compartment pharmacokinetic parameters in Table 1 . A comparison of the calculated noncompartmental pharmacokinetic parameters in the 12 study patients and published data (13) for healthy volunteers derived by similar methodology (i.e., in terms of assay procedure, blood sampling scheme, and kinetic data handling) is shown in Table 2 .
The observed mean Cm., was 47.58 ,ug/ml. Figure 1 shows the mean ± SD meropenem concentrations in serum versus time for the 12 study patients. Our study patients, on (4, 5, 9) . The increased meropenem volume of distribution in our study patients compared with that in healthy subjects may reflect physiologic changes of third spacing as a result of surgery (15) . Other pharmacokinetic parameters were noted to be different as well. In comparison with pharmacokinetic parameters in healthy volunteers, Cm., and AUC_O, are decreased, CLMER and mean residence time are increased, and CLR and kei are unchanged. Our confidence in the parameters of meropenem CLR and the secondarily derived nonrenal clearance term is limited by the short urine collection time of 4 h and the inability to account for residual bladder urine in these uncatheterized patients. Further, we cannot exclude the possibility of metabolic breakdown of meropenem during storage.
We have provided a description of meropenem pharmacokinetics as part of a multicenter, double-blind clinical trial with patients with intra-abdominal infections. The compartmental and noncompartmental pharmacokinetic parameters in this patient population differed from those estimates for healthy volunteers (2-5, 9, 10, 12, 13, 20) . Despite these differences, we conclude that meropenem (1,000 mg, intravenous piggyback) administered every 8 h provides therapeutic concentrations in serum for patients with intra-abdominal infections from susceptible organisms.
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